Novo Nordisk’s GLP-1 Franchise Buoyed By SUSTAIN FORTE data
Showed Superior Diabetes Risk-Benefit From Higher Ozempic Dose
Reductions in blood glucose seen in the SUSTAIN FORTE study using a higher dose of Ozempic may help type 2 diabetes patients further improve their diabetes control, with comparable tolerability to currently approved Ozempic 1.0 mg.
